GLP-1 receptor agonists in heart transplant recipients with type 2 diabetes
A retrospective study across 14 Spanish centers looked at heart transplant recipients with type 2 diabetes who were treated with GLP-1 receptor agonists. Over one year, researchers reported improvements in weight, blood sugar, cholesterol, and blood pressure, with generally good tolerability.
Type 2 diabetes is common after a heart transplant, and the medications used to prevent organ rejection can make blood sugar control harder. Researchers wanted to know whether GLP-1 receptor agonists, a class of drugs now widely used for diabetes and weight management, could help this specific and medically complex group of patients.
This was a study in people, not animals or cells. It was published in the journal Transplantation and drew on real-world medical records from 14 transplant centers in Spain. Because it looked back at care that had already happened rather than randomly assigning treatments, it is what scientists call a retrospective, observational study.
What the researchers studied
The team identified 734 heart transplant recipients with type 2 diabetes treated between 2011 and 2021. Of those, 108 people, about 14.7 percent, received a GLP-1 receptor agonist. Their average age was 55, and most were men. On average, treatment began four years after transplant, and nearly two-thirds of the group had obesity at the start.
The medications used varied. Semaglutide was the most common at 59 percent, followed by dulaglutide, liraglutide, and a small number on tirzepatide. Researchers tracked metabolic measures, insulin use, side effects, and the blood levels of immunosuppressant drugs over the first year after starting treatment.
What they reported
After one year, the group showed several statistically significant changes. Body weight fell by about 6.2 kg on average. Fasting glucose and glycated hemoglobin, a longer-term marker of blood sugar, both declined. Total cholesterol, LDL cholesterol, triglycerides, and systolic blood pressure also decreased.
Levels of tacrolimus, a common anti-rejection medication, dropped modestly. Importantly, the authors reported no episodes of acute organ rejection during the study period. Gastrointestinal side effects occurred in 12 percent of patients and led to stopping the medication in 3.7 percent.
What this does and does not establish
The study describes associations observed in one group of patients over time. It suggests GLP-1 receptor agonists can be used in heart transplant recipients with diabetes and were generally well tolerated in this sample. That is meaningful for a population where data have been scarce.
It does not prove cause and effect. Without a comparison group that did not receive these medications, the reported improvements cannot be attributed to the drugs alone. Other factors, including diet, lifestyle, and changes in other medications, may have contributed. The findings also apply to transplant recipients and should not be read as a promise of results for anyone else. Outcomes vary from person to person.
One honest limitation
Because this was a retrospective look at existing records rather than a controlled trial, the study cannot rule out bias in who was chosen for treatment. Patients prescribed GLP-1 receptor agonists may have differed in ways that affected their results. The authors themselves frame the work as supportive evidence, not definitive proof.
If you are considering this type of care
Transplant recipients have unique medical needs, and the modest change in tacrolimus levels seen here is a reminder that these medications interact with a person's full treatment picture. Any decision belongs with the clinicians managing your care.
Live Vital offers physician-prescribed semaglutide and tirzepatide through telehealth. Both require a medical intake and physician approval, and a physician determines whether treatment is appropriate. You can begin that process at get started or book a free consult at consult.